Form 4: Lyell Immunopharma CFO Granted 140,000 Stock Options

Lyell Immunopharma's Chief Financial and Business Officer, Smital Shah, was granted 140,000 stock options with a $25.5 exercise price, vesting over four years.

Summary

• Smital Shah, Lyell Immunopharma's Chief Financial and Business Officer, was granted 140,000 stock options.
• The options have an exercise price of $25.5 per share.
• The grant date for these options was March 9, 2026.
• The options expire on March 8, 2036.
• The vesting schedule dictates that 25% of the options will vest on March 9, 2027.
• The remaining options will vest in equal monthly installments over the subsequent 36 months, contingent on continued service.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine but positive development, indicating continued executive commitment and alignment with long-term shareholder interests through equity incentives.

Positives

• The grant of 140,000 stock options to a key executive (CFO) indicates continued commitment and alignment of interests with shareholders.
• The long-term vesting schedule (over four years) incentivizes long-term performance and retention of a senior executive.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, suggesting a pre-planned and orderly approach to executive compensation.

Negatives

• No immediate cash benefit to the executive, as these are options, not shares.
• Potential for dilution if all options are exercised in the future.

Risks

• The value of the options is contingent on the company's stock price appreciating above the $25.5 exercise price, posing a risk if the stock underperforms.
• The vesting schedule is subject to the reporting person providing service through the applicable vesting date, meaning unvested options could be forfeited if employment ceases.

Future Outlook

The future outlook for the granted options is tied to the company's stock performance, as the options will only be in-the-money if the stock price exceeds the $25.5 exercise price. The vesting schedule extends through March 2030, incentivizing long-term executive performance and retention.

Industry Context

StockSavvy.ai notes that the grant of stock options to a Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical industry, particularly for growth-oriented companies like Lyell Immunopharma. Such grants are designed to align executive incentives with long-term shareholder value creation and are a common component of executive compensation packages aimed at attracting and retaining top talent in a competitive sector.

Comparison to Industry Standards

• StockSavvy.ai observes that the grant of 140,000 options to a CFO, with a 10-year expiration and a four-year vesting schedule, is generally consistent with compensation practices for senior executives at similar-stage biotechnology companies.
• For instance, companies like Moderna (MRNA) or BioNTech (BNTX) often utilize substantial equity grants to incentivize leadership, though the specific number and exercise price would vary based on company size, market capitalization, and individual executive roles.
• The $25.5 exercise price suggests the options were likely granted at or above the market price on the grant date, a common practice to ensure executives are incentivized by future stock appreciation.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased long-term value creation due to executive incentives.
• Employees: May signal stability in executive leadership.

Next Steps

• Continued service by Smital Shah to ensure vesting of the options.
• Potential exercise of vested options by Smital Shah in the future, contingent on stock price performance.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event, specifically the grant of stock options to the CFO. While it aligns executive incentives with long-term shareholder value, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, pending further operational updates.

Keywords

Lyell Immunopharma, LYEL, stock options, executive compensation, Smital Shah, CFO, Form 4, insider transaction, equity grant, vesting schedule, Rule 10b5-1